New UAB-developed gene therapy for ALS receives orphan drug designation
The US Food and Drug Administration (FDA) has given an orphan drug design for a new gene therapy for the Ameotrophic Lateral Sclerosis (ALS) developed in Universitate Autonem de Barcelona and US company Clotho Neurosis, Inc. The drug uses a viral vector of AAV (Adeno-Juda Virus) type that expresses neuroregensing, antioxidants and anti-inflammatory properties with […]
